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Abstract. 
 
Calcineurin-dependent pathways have been
implicated in the hypertrophic response of skeletal
muscle to functional overload (OV) (Dunn, S.E., J.L.
 
Burns, and R.N. Michel. 1999. 
 
J. Biol. Chem
 
. 274:21908–
21912). Here we show that skeletal muscles overex-
pressing an activated form of calcineurin (CnA*) ex-
hibit a phenotype indistinguishable from wild-type
counterparts under normal weightbearing conditions
and respond to OV with a similar doubling in cell size
and slow ﬁber number. These adaptations occurred de-
spite the fact that CnA* muscles displayed threefold
higher calcineurin activity and enhanced dephosphory-
lation of the calcineurin targets NFATc1, MEF2A, and
MEF2D
 
.
 
 Moreover, when calcineurin signaling is com-
promised with cyclosporin A, muscles from OV wild-
type mice display a lower molecular weight form of
CnA, originally detected in failing hearts, whereas
CnA* muscles are spared this manifestation. We also
show that OV-induced growth and type transforma-
tions are prevented in muscle ﬁbers of transgenic mice
overexpressing a peptide that inhibits calmodulin from
signaling to target enzymes. Taken together, these ﬁnd-
ings provide evidence that both calcineurin and its ac-
tivity-linked upstream signaling elements are crucial for
muscle adaptations to OV and that, unless signiﬁcantly
compromised, endogenous levels of this enzyme can ac-
commodate large ﬂuctuations in upstream calcium-
dependent signaling events.
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phy • calcium
 
 
 
signaling
 
Introduction
 
Skeletal muscle fibers adapt to higher contractile loads by
 
increasing their size and by expressing slower isoforms
of muscle contractile proteins (Dunn and Michel, 1997).
 
Calcineurin, a Ca
 
2
 
1
 
/calmodulin(CaM)
 
1
 
-dependent phos-
phatase, appears crucial in the signaling of this adaptive
response, since functional overload-induced fiber hyper-
trophy and fiber type transformations are prevented in
vivo by administration of the specific calcineurin inhibitors
cyclosporin A (CsA) and FK506 (Dunn et al., 1999). Cal-
cineurin is likely activated in overloaded muscles via the
chronic increases in intracellular calcium that occur under
these conditions (Panchenko et al., 1974) as a result of a
doubling of nerve-mediated muscle fiber activation (Gar-
diner et al., 1986) and load-related increases in insulin-like
growth factor (Adams and Haddad, 1996; Musaro et al.,
1999; Semsarian et al., 1999). Once activated, calcineurin
may signal downstream to genes involved in regulating
muscle fiber size and myofibrillar protein phenotype via
dephosphorylation of its substrate transcription factors,
nuclear factor of activated T cells (NFAT) and myocyte
enhancer factor 2 (MEF2) (Chin et al., 1998; Musaro et al.,
1999; Semsarian et al., 1999; Wu et al., 2000).
Recently, a 10-fold overexpression of transcripts encod-
ing a constitutively active form of the catalytic subunit of
calcineurin (CnA*) has been shown to promote fast-to-
slow fiber type transformations, but not fiber hypertrophy,
in skeletal muscles of transgenic (Tg) mice under normal
weightbearing conditions (Naya et al., 2000). Though
these data corroborate original findings in cell culture with
respect to the influence of calcineurin on slow fiber–spe-
cific genes (Chin et al., 1998), they suggest that upstream
signaling effectors of this enzyme (i.e., nerve-mediated
muscle activation and mechanical loading, insulin-like
growth factor, etc.) are prerequisite to the initiation of
muscle fiber growth. In support of the latter notion, retro-
viral-mediated gene transfer of CnA* has been shown to
induce differentiation of skeletal myocytes only in the
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presence of extracellular calcium, the efficacy of which is
dose dependent (Friday et al., 2000). This, together with
reports that calcineurin acts in synergy with other calcium-
dependent enzymes to activate the expression of gene tar-
gets in both muscle cells and T lymphocytes (O’Keefe et
al., 1992; Wu et al., 2000), supports the contention that ad-
ditional pathways may be involved in signaling muscle fi-
ber growth (Murgia et al., 2000).
We thus tested the hypothesis that Tg mice expressing
CnA* would display muscle fiber growth and more exten-
sive fast-to-slow fiber type conversions when upstream sig-
naling effectors of this enzyme are activated by functional
overload (OV). We also investigated whether interference
of Ca
 
2
 
1
 
/CaM signaling would mimic the effects of cal-
cineurin inhibitors (Dunn et al., 1999) and prevent these
OV-induced fiber adaptations. To this end, Tg mice were
generated that expressed either a transgene that encoded
CnA* (O’Keefe et al., 1992), or a peptide (CaMBP) that
binds Ca
 
2
 
1
 
/CaM complexes and inhibits their signaling to
CaM-dependent enzymes (Wang et al., 1995). We show
that despite 3-fold higher calcineurin activity and enhanced
dephosphorylation of
 
 
 
its targets, NFATc1, MEF2A, and
MEF2D, a 10-fold overexpression of CnA* mRNA did not
influence fiber size nor fiber type proportions under nor-
mal contractile conditions, but matched the upstream func-
tional requirements related to OV by displaying a similar
doubling in size and slow fiber number as wild-type (WT)
counterparts. Moreover, when calcineurin signaling was
compromised with CsA, overexpression of CnA* spared
overloaded muscles the appearance of a lower relative mo-
lecular weight form of this protein that was first identified
in failing human hearts (Tsao et al., 2000). Finally, we show
that OV-induced hypertrophy and fast-to-slow contractile
protein type transitions were prevented in fibers expressing
the CaMBP transgene. These results emphasize that cal-
cineurin is a crucial signaling element in the induction of
skeletal muscle fiber hypertrophy and fiber type conver-
sions in response to increased contractile loading and show
that this enzyme requires its upstream activators to effec-
tively signal this adaptive response.
 
Materials and Methods
 
Tg Mice and Genotyping
 
CnA* Tg mice (C57/BL6 strain) were generated by overexpressing CnA*
cDNA (O’Keefe et al., 1992) linked to either the muscle creatine kinase
(MCK) promoter (Sternberg et al., 1988) or the myosin light chain
(MLC)1f/3f promoter (Rosenthal et al., 1989). CaMBP Tg mice (ICR
strain) were generated by overexpressing a CaMBP (Wang et al., 1995)
linked to the human troponin I slow (TnIs) promoter (Corin et al., 1994).
Transgenes were linearized and separated from bacterial vectors by elec-
trophoresis and electroelution. Tg mice were generated by pronuclear in-
jection of the transgene into fertilized embryos of mice using standard
procedures (Hogan et al., 1994). Surrogate mothers gave birth to founder
lines of Tg mice. Positive founders were identified and then crossed with
WT mice of the same strain to generate F1 and F2 progeny. Stable lines of
mice were generated from Tg offspring of F1 and F2 lines.
Founder Tg mice were identified by Southern blot analysis and their
genotype confirmed using PCR screening. PCR was used to genotype
subsequent generations of mice. Genomic DNA extracted from tail sam-
ples was used for these purposes. For PCR screening of CnA* Tg mice,
genomic DNA was amplified using a sense primer specific for CnA*
cDNA and an antisense primer specific for the SV-40 polyA of this trans-
gene. A similar approach was used to screen CaMBP Tg mice. PCR reac-
tion mixtures contained 0.5 
 
m
 
g of DNA, 10 mM dNTP, 200 ng of each
 
primer, 1.5 mM
 
 
 
MgCl
 
2
 
, PCR buffer, and 5 U of Taq polymerase (Qiagen
Inc.). Cycling conditions were: 94
 
8
 
C for 5 min followed by 25 cycles of 30 s
at 94
 
8
 
C, 1 min at 50
 
8
 
C, and 1 min at 72
 
8
 
C followed by a final 10-min exten-
sion at 72
 
8
 
C.
 
Northern Blot Analysis of CnA mRNA Expression
 
RNA was isolated from white gastrocnemius muscle using tripure isola-
tion reagent (Boehringer) and resuspended in diethyl pyrocarbonate
(DEPC)-H
 
2
 
0. RNA (15 
 
m
 
g) was separated on a formaldehyde-2% agarose
gel and transferred to a nylon membrane by capillarization. Membranes
were probed with a 400-bp cDNA fragment from the CnA* transgene or a
340-bp cDNA fragment of the CaMBP transgene, labeled with [
 
a
 
32
 
P]
dATP and dCTP. Skeletal actin served as a loading control. Bands were
detected using autoradiography.
 
RT-PCR and Calcineurin Phosphatase Assay
 
RNA was extracted from the distal portion of each plantaris muscle and 1
 
m
 
g of total RNA was reverse-transcribed to cDNA (Dunn et al., 1999).
cDNAs encoding type I myosin heavy chain (MHC), type IIb MHC, TnIs,
troponin I fast (TnIf), and the 28 S rRNA subunit were PCR amplified us-
ing primers specific to these mRNA sequences (Dunn et al., 1999). CnA
 
a
 
cDNAs were amplified using primers designed from the mouse mRNA se-
quence (available at GenBank/EMBL/DDBJ under accession number
ACJ05479): sense, 5
 
9
 
-GGTGGCTGGAGATGTCCGAGC-3
 
9
 
 (mRNA
positions 65–85) and antisense, 5
 
9
 
-GGTGGTTCTTTGAATCGGTC-3
 
9
 
(complementary to mRNA positions 721–740). GATA-2 cDNAs were
amplified using primers designed from the mouse mRNA sequence (avail-
able at GenBank/EMBL/DDBJ under accession number AB000096):
sense, 5
 
9
 
-CAACCATCTCGACTCGCAGG-3
 
9
 
 (mRNA positions 301–
320) and antisense, 5
 
9
 
-GTGGGTGGGAAGCCGAAGAG-3
 
9
 
 (compli-
mentary to mRNA positions 662–681). PCR reaction mixtures contained
2.5 
 
m
 
l of cDNA, 5 mM each dNTP, 10 pmol of each primer, 1.5 mM
MgCl
 
2
 
, PCR buffer, and 0.65 U Taq (QIAGEN). Cycling conditions were:
1 min at 95
 
8
 
C, 1 min at 55
 
8
 
C, and 1 min at 72
 
8
 
C, followed by a final 5-min
extension at 72
 
8
 
C. Cycle number was adjusted to permit comparison of
PCR products across treatments within the linear phase of amplification.
Products were run on 1% agarose–tris boric acid EDTA gels and stained
with ethidium bromide.
Total calcineurin phosphatase activity was measured in plantaris homog-
enates by Isotechnika Inc. using a modification of a previously described
assay (Fruman et al., 1992). In brief, tissue samples (
 
z
 
25 mg) were me-
chanically disrupted by grinding in liquid nitrogen and then suspended in
200 
 
m
 
l lysis buffer (50 mM Tris, pH 8.0, 1 mM EDTA, 100 
 
m
 
M EGTA,
0.1% 
 
b
 
-mercaptoethanol, 1 mM DTT, and 50 
 
m
 
g/ml of aprotinin). Samples
were centrifuged and then the supernatant was diluted further with lysis
buffer (1:4). An aliquot (30 
 
m
 
l) of each lysate was combined with 60 
 
m
 
l of
assay buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 6 mM MgCl
 
2
 
,
 
 
 
500 mM
DTT, 100 
 
m
 
g/ml BSA, 750 nM okadaic acid, 100 
 
m
 
M CaCl
 
2
 
, 100 nM CaM,
and 15 
 
m
 
M of 
 
32
 
P-labeled–RII subunit of cAMP-dependent protein kinase)
and samples were incubated at 30
 
8
 
C in the presence or absence of 1,500 ng/
ml of CsA. After 15 min, reactions were stopped with 100 mM KH
 
2
 
PO
 
4
 
/5%
trichloroacetic acid. The released inorganic phosphate was isolated using a
Dowex cation–exchange column and measured via scintillation counting.
 
Protein Extraction and Western Blot Analysis
 
For extraction of whole cell protein, muscle samples (
 
z
 
25 mg) were ho-
mogenized in 150 
 
m
 
l of RIPA buffer (1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin, 1 mM
PMSF, 10 mM sodium fluoride, 1 mM sodium orthovanadate in PBS, pH
7.4). Homogenates were centrifuged at 20,000 
 
g 
 
for 15 min at 4
 
8
 
C to ob-
tain a clarified supernatant.
Plantaris extracts enriched in nuclear proteins were prepared according
to the method of Blough et al. (1999). An equivalent amount of muscle tis-
sue (
 
z
 
25 mg) was homogenized in ice-cold lysis buffer (10 mM Hepes, pH
7.5, 10 mM MgCl
 
2 
 
5 mM KCl, 0.1 mM EDTA, pH 8.0, 0.1% Triton X-100,
1 mM DTT, 0.1 mM PMSF, 2 
 
m
 
g/ml each aprotinin and leupeptin) and
centrifuged at 3,000 
 
g
 
 for 5 min at 4
 
8
 
C to pellet nuclei and myofibrils. This
pellet was then resuspended in 1 ml of ice-cold, high-salt buffer (20 mM
Hepes, pH 7.9, 25% glycerol, 500 mM NaCl, 1.5 mM MgCl
 
2
 
, 0.2 mM
EDTA, pH 8.0, 0.5 mM DTT, 0.2 mM PMSF, 2 
 
m
 
g/ml each leupeptin and
aprotinin) for 30 min and then samples were centrifuged at 3,000 
 
g
 
 for 5
min at 4
 
8
 
C. The supernatant, enriched in nuclear proteins, was then con-
centrated to 75 
 
m
 
l using a 5000 nominal molecular weight limit 4 ml Ul- 
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trafree
 
®
 
 Filter Unit (Millipore). The protein concentration within each to-
tal cell and nuclear extract sample was determined with a Bradford assay
using BSA as a standard. Whole cell and nuclear extracts were suspended
in 1 vol of 2
 
3
 
 electrophoresis sample buffer.
Each whole cell and nuclear sample (50–100 
 
m
 
g) was subjected to
6–12% SDS-PAGE electrophoresis and then transferred to PVDF mem-
brane (Amersham Pharmacia Biotech). Equal loading of samples was ver-
ified via Coomassie blue staining of gel proteins and Ponceau S staining of
membrane-bound proteins
 
. 
 
For Western blotting, membranes were
blocked in BLOTTO (5% milk, 0.1% Tween-20 in TBS, pH 8.0) for 1 h
and then incubated for an additional hour with primary antibodies diluted
in BLOTTO. Membranes were rinsed with 0.1% Tween-20 in TBS and
then incubated for 1 h with horseradish peroxidase secondary antibody
conjugates diluted in BLOTTO. Bound antibody complexes were devel-
oped using the ECL Plus kit and exposed to Hyperfilm ECL-Plus x-ray
film (Amersham Pharmacia Biotech).
Antibodies used in this study were raised against: NFATc1 (Affinity
Bioreagents, Inc. and Santa Cruz Biotechnology, Inc.), MEF2A (Santa
Cruz Biotechnology, Inc. and gift from R. Prywes, Columbia University,
New York, NY), MEF2D (gift from R. Prywes), CnA
 
b
 
 (StressGen Bio-
technologies), and CnA
 
a
 
 (Oxford Biomedical Research Inc. and Santa
Cruz Biotechnology, Inc.). The MEF2A and MEF2D antibodies obtained
from R. Prywes cross-react with MEF2C and were used to estimate the
abundance of this protein in nuclear extracts. The CnA antibody (Stress-
Gen Biotechnologies) is raised against an epitope (FLQNNNLLSIIRA-
HEAQDAG, amino acids 264–283) in the catalytic region of human
CnA
 
b
 
 (see Fig. 4 a), which is completely conserved in mouse CnA
 
b
 
(available at GenBank/EMBL/DDBJ under accession number M81483).
Anti-CnA
 
a
 
 (Oxford) is raised against an epitope (RMPPRRDAMPSDA,
amino acids 482–494) in the COOH terminus of human CnA
 
a
 
, which is
fully conserved in mouse CnA
 
a
 
 (available at GenBank/EMBL/DDBJ un-
der accession number J05479), and partially conserved in and cross-react-
ing with mouse CnA
 
b
 
 (8 of 13 residues). Anti-CnA
 
a
 
 (Santa Cruz Biotech-
nology, Inc.) is also raised against an epitope in the COOH terminus of
this protein, but does not recognize other CnA isoforms.
 
Functional Overload Surgery and CsA Administration
 
The plantaris muscle in each hindlimb of WT, CaMBP Tg, and CnA* Tg
mice was overloaded by surgically removing the soleus and a major por-
tion of the gastrocnemius muscle (Dunn et al., 1999). Some WT, MCK-,
and MLC-CnA* Tg mice were also injected twice daily (12 h apart) with
25 mg/kg CsA (Dunn et al., 1999). This dose of CsA resulted in blood lev-
els of this drug of 2,865 
 
6
 
 517 ng/ml. Administration of this drug did not
affect the health, growth nor noticeably alter the daily amount of locomo-
tor activity displayed by these mice. After a 5-d or 4-wk treatment period,
muscles were removed and quick frozen in melting isopentane. All surgi-
cal procedures were performed on mice anesthetized with a 100 mg/ml
ketamine hydrochloride: 20 mg/ml xylazine cocktail in a volume ratio of
(1.6:1). Treatment of animals was in accordance with the guidelines estab-
lished by the Canadian Council on Animal Care.
 
Fiber Typing and Cross-sectional Size Measurements
 
Cryosections (10 
 
m
 
m) were cut from the same anatomical location in each
muscle midbelly. Sections were blocked for 1 h in 5% goat serum in PBS
and then probed with mouse antibodies specific for MHC type I (BA-F8),
IIa (SC-71), IIb (BF-F3), or all MHCs but IIx (BF-35), followed by horse-
radish peroxidase–conjugated goat anti–mouse IgG or IgM (Dunn and
Michel, 1997). Antibody complexes were visualized using diaminobenzi-
dine tetrahydrochloride. Fibers that expressed MHC type I, IIa, IIx only,
or IIb were identified within three distinct areas of each muscle cross-sec-
tion. Images of these areas were captured and fiber cross-sectional size
measured using a microscope linked to a computer-based image analysis
system (Dunn and Michel, 1997). Fiber size values for each group were
calculated as the mean (
 
n
 
 = 3–4 muscles/group) of muscle fiber means (
 
n
 
 =
20–60 fibers/muscle section).
 
Results
 
Generation of Mice Expressing Functional CnA*
 
Tg mice were generated that overexpressed CnA* either
under the control of the MCK promoter which is active in
 
all muscle fibers, or the fast MLC promoter which is oper-
ative only within fast fiber types and in the mouse plan-
taris represent 
 
z
 
98% of the total fiber population. CnA*
encodes a deletion mutant of the 
 
a
 
 isoform of murine CnA
that lacks the COOH terminus autoinhibitory and CaM-
binding domains, and displays constitutive activity in vitro
(O’Keefe et al., 1992).
 
 
 
Five independently derived founder
Figure 1. Overexpression of CnA* mRNA increases calcineurin
activity in plantaris muscles. (a) Northern blots of CnA* mRNA
expression in the plantaris of WT, MCK-, and MLC-CnA*-Tg
mice. Loading control was a-skeletal actin. Arrows indicate the
size of the 4.0 (upper) and 3.6-kB (lower) endogenous CnA tran-
scripts. Note, the minor endogenous 1.6-kB CnA form is not
shown. (b) RT-PCR analysis of total CnAa mRNA (endogenous
plus transgene) expression in MCK-CnA* mice. Lanes are ethid-
ium bromide-stained PCR products generated from individual
muscle cDNA samples. The 28 S rRNA served as a loading con-
trol. (c) Mean 6 SE of total calcineurin activity in WT and MCK-
CnA* Tg plantaris muscles (n 5 three muscles/group). The aster-
isk denotes a difference (P , 0.05) from WT. 
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mice were generated for each construct. For MCK-CnA*,
four of five founders transmitted the transgene to the F
 
1
 
generation and, of these, only one line (5237) showed
CnA* expression at the mRNA level (Fig. 1 a). For the
MLC-CnA* construct, three of five founders produced Tg
offspring and only one line of mice (2276) expressed de-
tectable levels of CnA* mRNA (Fig. 1 a). Tg mice from
MCK-CnA* (5237) and MLC-CnA* (2276) lines were
used in this study. CnA* mRNA was expressed at levels
that were 
 
.
 
10-fold higher than endogenous CnA in both
5237 and 2276 lines as assessed by Northern blot or RT-
PCR analyses (Fig. 1, a and b). The expression of the
transgene also resulted in threefold higher calcineurin
phosphatase activity in the plantaris of MCK-CnA* Tg
mice (Fig. 1 c), demonstrating that the CnA* transgene
was functional in this muscle.
 
CnA* Expression and OV Increase CnA Signaling via 
NFATc1 and MEF2
 
Activation of calcineurin in skeletal myocytes has been
shown to induce the dephosphorylation and nuclear local-
ization of the NFATc1 transcription factor (Abbott et al.,
1998; Chin et al., 1998; Musaro et al., 1999; Semsarian et
al., 1999). Thus, to assess the relative influence of the
CnA* transgene versus upstream activity-dependent effec-
tors on calcineurin signaling, we examined the phosphory-
lation status and nuclear abundance of this calcineurin sub-
strate in the plantaris of WT and MCK-CnA* Tg mice
subjected to normal weightbearing or functional OV con-
ditions. Consistent with previous findings in skeletal myo-
cytes (Musaro et al., 1999; Semsarian et al., 1999), multiple
NFATc1 bands ranging from 85–142 kD were detected on
Western blots of plantaris whole cell and nuclear extracts
(Fig. 2 a). Pretreatment of protein extracts with alkaline
phosphatase produced only two lower molecular weight
species of 
 
z
 
85 and 90 kD, suggesting that the detected
NFATc1 bands correspond to the hypophosphorylated (85
and 90 kD) and phosphorylated (
 
.
 
90 kD) forms of possi-
bly two variants of this protein (see Rao et al., 1997). The
sole difference in NFATc1 banding pattern between whole
cell and nuclear isolates was the absence of the highest mo-
lecular weight 142-kD band in the nuclear fraction (Fig. 2
a), consistent with the notion that only a partial dephos-
phorylation of NFAT is required to uncover its nuclear lo-
calization signal and promote its nuclear import (Musaro
et al., 1999). Expression of the CnA* transgene induced a
subtle dephosphorylation of NFATc1 and an enrichment
of this transcription factor in the nuclear fraction of the
plantaris of normal weightbearing mice (Fig. 2 a, Con [con-
trol], compare lanes WT and Tg). Interestingly, OV alone
induced a dephosphorylation of NFATc1 that was similar
to that observed in CON MCK-CnA* Tg mice, indicating
that the response
 
 
 
was
 
 
 
not potentiated by the CnA* trans-
gene (Fig. 2 a, compare lanes OV and Con Tg). These ef-
fects of OV on NFATc1 in both treatment groups were
blocked by administration of CsA (Fig. 2 a, compare lanes
OV and OV-CSA). Taken together, these data suggest
that CnA* expression and OV each activate calcineurin-
dependent signaling in vivo
 
 
 
and that the combined effect
of these treatments on the dephosphorylation and nuclear
translocation of NFATc1 is not additive.
A series of recent studies provide evidence that cal-
cineurin may also target downstream genes through the
dephosphorylation and activation of MEF2 transcription
factors (Mao and Wiedmann, 1999; Blaeser et al., 2000;
Wu et al., 2000).
 
 
 
Moreover, and of considerable signifi-
cance, MEF2 cis-elements have been implicated in the reg-
ulation of a number of slow fiber–specific promoters (Chin
et al., 1998; Esser et al., 1999). We thus investigated
whether proteins of this family are dephosphorylated by
calcineurin under MCK-CnA* Tg or OV conditions. We
found that overexpression of CnA* alone induced a prom-
inent dephosphorylation of MEF2D and a subtle dephos-
phorylation of MEF2A in normal weightbearing plantaris
muscles as assessed by Western blots (Fig. 2 b). Like
NFATc1, the prominent effect of the transgene on
MEF2D dephosphorylation appeared to be matched by
the effect of OV, with no observable amplification of this
response in overloaded mice expressing CnA*. This de-
phosphorylation of MEF2D under these conditions ap-
peared to be calcineurin-dependent since it was blocked
by CsA administration (Fig. 2 b). By far the major
 
 
 
influ-
ence on MEF2A was a pronounced dephosphorylation
and increased abundance with OV, effects that were not
potentiated by CnA* and only partly blocked by treat-
ment with CsA (Fig. 2 b). The latter suggests that this tran-
scription factor may act as both substrate and gene target
of calcineurin. In contrast, expression of CnA* or OV did
not produce any noticeable change in the mobility or
Figure 2. Effect of CnA* expression, OV, or OV plus CsA treat-
ments on the phosphorylation status of NFATc1 and MEF2. (a)
Western blots of NFATc1 in whole cell and nuclear extracts, and
MEF2C in nuclear extracts, of WT and MCK-CnA* Tg plantaris
muscles after 5 d of the various treatment conditions. Note the
banding pattern for NFATc1 was obtained using two distinct anti-
bodies raised against this protein (data not shown). MEF2C served
as a loading control for nuclear extracts. (b) Western blot analysis
of the total protein content of MEF2D and MEF2A in plantaris
muscles of WT and MCK-CnA* Tg mice after 5 d of the various
treatments. In a and b, filled arrows denote hypophosphorylated
forms of each protein as determined by pretreatment of samples
with alkaline phosphatase (1AP). Results in a and b represent the
observations of three or more independent experiments. 
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abundance of MEF2C (Fig. 2 a), suggesting that this
MEF2 isoform is not a target of this phosphatase. Taken
together with NFATc1 findings, these data show that ex-
pression of CnA* promotes calcineurin signaling via
NFATc1, MEF2A, and MEF2D in the plantaris under
normal weightbearing conditions. Our data also show the
effects of the CnA* transgene on these transcription fac-
tors to be largely matched, and in the case of MEF2A sur-
passed, by the effects of OV.
 
Calcineurin Requires Its Upstream Effectors to 
Promote Fiber Type Transitions and Growth
 
To assess the influence of upstream activity-dependent
calcineurin effectors on the determination of the skeletal
muscle phenotype, we examined plantaris fiber size and
type proportions in WT, MCK-CnA* Tg, and MLC-CnA*
Tg mice exposed to normal weightbearing or functional
OV conditions. As expected, by 4 wk of OV we noted a
doubling of plantaris relative mass (Fig. 3 a) and fiber
Figure 3. Overexpression of CnA* did not potentiate the hypertrophic response of plantaris muscles to OV or induce the expression of
GATA-2. (a) Effect of 4 wk of OV on plantaris relative wet weight (MW) (mg/g body weight, BW) in WT and Tg mice. Values are means 6
SE (n 5 4–9/group). Asterisks denote a difference (P , 0.01) from respective sham control groups. (b) Effect of 4 wk of OV on the ratio of
plantaris fiber cross-sectional area (CSA) relative to respective sham control values (broken line) for each fiber type in WT and Tg mice.
Fiber CSA was measured in 20–60 fibers/muscle for 3–4 muscles/group. In this histogram, all bars are significantly different (P , 0.05)
from respective sham controls which were not different from one another. (c) Effect of 4 wk of OV on the number of slow type fibers in
the plantaris of WT and Tg mice. Values are means 6 SE (n 5 3–4/group). Asterisks denote a difference (P , 0.01) from the respective
sham control. (d) RT-PCR analysis of transcript levels for TnIs, type I MHC, TnIf, IIb MHC, and 28 S rRNA in WT and MCK-CnA* Tg
tissues after CON and 4 wk of OV. Lanes show ethidium bromide–stained PCR product bands generated from individual muscle cDNA
samples. The 28 S rRNA served as a loading control. (e) Western blots of GATA-2 protein and RT-PCR analysis of GATA-2 mRNA ex-
pression in WT and MCK-CnA* Tg mice after 5 d of CON, OV, or OV plus CsA treatments. For PCR, lanes represent PCR product
bands generated from pooled cDNA samples (n 5 2/group). 28S rRNA expression was not different across treatments (not shown).The Journal of Cell Biology, Volume 151, 2000 668
cross-sectional size (Fig. 3 b) in WT mice. OV-WT plan-
taris muscles also displayed a characteristic increase in the
number of fibers that expressed type I/slow MHC (Fig. 3
c), and, consistent with our previous findings (Dunn et al.,
1999), a reciprocal elevation in transcript levels of slow fi-
ber–specific genes (TnIs and I MHC) and decreased ex-
pression of fast (TnIf and IIb MHC) myofibrillar genes,
compared with CON counterparts (Fig. 3 d).
OV plantaris muscles that overexpressed CnA* (MCK-
CnA* and MLC-CnA*) displayed a doubling in muscle
mass (Fig. 3 a), fiber size (Fig. 3 b), and slow fiber number
(Fig. 3 c), and increased expression of slow fiber–specific
genes (Fig. 3 d) that was similar to WT counterparts. To
our surprise, overexpression of CnA* did not influence
slow fiber number (Fig. 3 c) or the expression of slow fi-
ber–specific genes (Fig. 3 d) in the plantaris under normal
contractile conditions, which is in sharp contrast to a recent
study reporting fast to slow fiber transitions in mice that
overexpressed this same transgene at comparable levels
(Naya et al., 2000). Finally, expression of CnA* did not in-
fluence satellite cell differentiation, a process reported to
be regulated by calcineurin (Friday et al., 2000), since the
amount of central-nucleated fibers in histological sections
was insignificant (range 5 0–3 fibers/muscle section for all
three groups) and not different between WT and Tg mice.
In light of the fact that none of the known targets of cal-
cineurin measured above were up-regulated in response to
expression of the CnA* transgene alone, we elected to as-
sess the expression levels of GATA-2, another purported
target of calcineurin implicated in skeletal myocyte hyper-
trophy (Musaro et al., 1999), in the plantaris of WT and
MCK-CnA* Tg mice after CON and OV conditions. Sur-
prisingly, muscles overexpressing CnA* did not display in-
creased amounts of GATA-2 at the protein or mRNA lev-
els (Fig. 3 e, Con, compare lanes WT and Tg). Moreover,
although GATA-2 protein content was increased with OV,
levels were even higher after CsA treatment (Fig. 3 e). In
contrast to protein findings, GATA-2 mRNA levels were
not significantly altered in response to the various treat-
ment conditions (Fig. 3 e). These data suggest that this gene
may be important for the OV response, but is not a major
target of calcineurin in vivo. Taken together with muscle
phenotype data, these findings suggest that calcineurin re-
quires its upstream activity-dependent effectors to activate
fast-to-slow fiber conversions and initiate fiber hypertro-
phy. These results also suggest that the level of nerve-medi-
ated activity or mechanical loading is a better predictor of
muscle fiber adaptations than the degree of calcineurin ac-
tivation in these muscles.
CnA* Expression Prevents Appearance of a Shorter 
CnA Variant in OV-CsA Muscles
Recently, evidence has been presented that failing human
hearts display a shorter, constitutively active, variant of
CnA that is very similar to the deletion mutant CnA* har-
bored in our mice (Tsao et al., 2000). It is proposed that the
manifestation of this form may serve as a molecular indica-
tor of the inability of the endogenous calcineurin pool to
meet the signaling requirements of contractile activity.
Here we show that a lower relative molecular mass form of
CnAb, the most abundant skeletal muscle CnA isoform
(Dunn, S., and R.N. Michel, unpublished observations),
appears in skeletal muscle of WT mice under conditions of
OV stress when calcineurin activity is severely compro-
mised (decreased by 60%) by CsA. This phenomenon was
not observed in OV MCK-CnA* Tg mice, suggesting that
under these conditions the additional calcineurin activity is
available to match upstream activity-related requirements.
Using an antibody raised against an epitope in the catalytic
Figure 4. Overexpression of CnA* prevents the appearance of a
lower relative molecular weight form of CnA in OV muscles when
CnA signaling is compromised with CsA. (a) Cartoon depicting
the catalytic, regulatory subunit-binding (CnB), CaM-binding
(CaM), and auto-inhibitory (AI) domains of CnA and the location
of epitopes recognized by the antibodies used in this study. The
filled arrow shows the approximate location of where this protein
is cleaved or prematurely terminated. (b) Western blots of plan-
taris protein extracts from WT or MCK-CnA* Tg mice after CON,
OV, or OV plus CsA (OV-CsA) treatments probed with an anti-
body raised against an epitope in the catalytic region of CnAb
(top) or epitopes in the COOH terminus of CnAa or CnAb (mid-
dle and bottom). The antibody used for Western blots in the mid-
dle panel cross-reacts with, and primarily detects CnAb, the most
abundant CnA isoform in skeletal muscle (see Materials and
Methods), whereas the CnAa antibody used in the bottom panel
recognizes only CnAa. Note that all three isoforms of CnA mi-
grate to the same position on SDS-PAGE gels. The identity of the
upper band in the middle panel is not known, but may represent a
post-translational modification of CnA. c, Western blot analysis of
plantaris extracts from WT mice of the CD-1 strain after the vari-
ous treatment conditions probed with anti-CnAb (catalytic). Ar-
rows in b and c denote the size of full length CnAa and b (64 kD).Dunn et al. Calcineurin and Skeletal Muscle Growth 669
domain of CnAb (Fig. 4 a), we detected the full-length
CnA form (64 kD) as well as a band of lower molecular
weight on Western blots (Fig. 4 b, top, lane OV-CSA) cor-
responding to the reported size of a proteolysed form of
CnA that displays Ca21-independent, constitutive activity
(Hubbard and Klee, 1989). This smaller CnA form is likely
the result of a COOH-terminal deletion, since it was not
detected, even after long exposures to film, with an anti-
body that recognizes the COOH terminus of this protein
(see Fig. 4, a and b, middle panel, lane OV-CSA WT). This
lower relative molecular mass form was also detected in
OV-CsA–treated plantaris muscles from another strain of
mice (Fig. 4 c). Although the antibody used in the middle
panel in Fig. 4 b recognizes both CnAa and CnAb, the
form detected in this Western blot likely corresponds to
CnAb, since the observed pattern of expression across
treatments differs from that obtained using another anti-
body that only recognizes CnAa (Fig. 4 b, bottom, see also
Materials and Methods).
CaMBP Expression Prevents OV-related Fiber 
Hypertrophy and Fast-to-Slow Fiber Conversions
To further explore the role of calcineurin in regulating fi-
ber growth, we generated Tg mice that express a synthetic
peptide that binds to, and inhibits the ability of Ca21/CaM
complexes to activate CaM-dependent enzymes (Wang et
al., 1995). CaMBP was expressed in skeletal muscles under
the control of the TnIs promoter, which restricts expres-
sion of this transgene to the slow/I MHC fiber population.
Though these fibers constitute only a small contingent
(z2%) of plantaris cells in control mice, they are amongst
the smallest and most highly recruited fibers in this muscle
(Gardiner et al., 1986), and during OV are amongst the
first to undergo a rapid doubling of size and a tripling in
their numbers (Fig. 3 c; Dunn et al., 1999). Four indepen-
dently derived founder mice were generated that ex-
pressed the CaMBP transgene and all founders transmit-
ted the transgene to the F1 generation. Of these, only one
line (6444) showed high level expression of CaMBP at the
mRNA level (Fig. 5 a) and was used for this study. Here
we show that in OV animals, expression of CaMBP com-
pletely blocked the growth of plantaris slow/type I fibers
which harbored the transgene, but not fast/type II, fibers
(Fig. 5, b vs. c and d), and prevented the characteristic fast-
to-slow fiber conversions (slow fiber No. 5 24 6 8, OV
CaMBP vs. 59 6 4, OV WT; P , 0.05). Consistent with
our previous findings (Dunn et al., 1999), OV-induced hy-
pertrophy was also prevented across all fiber types when
mice were administered CsA (Fig. 5 d). Moreover,
CaMBP only influenced the growth and transformation of
slow/type I fibers under conditions of overload, since type
I fiber size (582 6 110 mm2) and slow fiber number (28 6
6) in CON CaMBP plantaris muscles were not different
from CON WT counterparts. In the predominantly slow
soleus, type I fibers were also not significantly affected by
the expression of the CaMBP transgene (data not shown),
supporting the notion that calcineurin is of major impor-
tance only when contractile loading is increased above
normal levels. Taken together, these results emphasize
that calcineurin and other Ca12/CaM-dependent pathways
are critical for the signaling of muscle fiber growth and
fast-to-slow conversions in response to increased loads.
Discussion
Calcineurin, a Ca21/CaM-dependent phosphatase, has
been implicated in the hypertrophic response of skeletal
muscles to increased physiological loads (Dunn et al.,
1999). The recent finding that expression of an activated
form of Cna in skeletal muscles in vivo is not sufficient to
induce fiber hypertrophy (Naya et al., 2000), suggests that
the upstream effectors of this enzyme (i.e., activity-related
increases in cytosolic Ca21) are required for the initiation
of skeletal muscle growth. Expanding upon this notion, we
show that skeletal muscles overexpressing an activated
CnA transgene, despite displaying threefold higher cal-
cineurin activity and enhanced dephosphorylation of tar-
get substrates, exhibited fiber sizes and fiber type profiles
indistinguishable from WT counterparts under normal
weightbearing conditions. Moreover, these muscles did not
display potentiated fiber growth or more extensive fast-to-
slow fiber conversions in response to OV. On the other
Figure 5. Overexpression of CaMBP in slow fibers prevented
hypertrophy of these cells in response to 4 wk of OV. (a) North-
ern blot analysis of CaMBP mRNA expression in WT and Tg
mice. a-skeletal actin served as a loading control. (b and c) Cross-
sections from OV WT (b) or OV CaMBP Tg (c) plantaris muscles
immunolabeled for type I MHC. Bar, 100 mm. (d) Mean 6 SE
cross-sectional size of plantaris fibers of CON WT, OV WT, OV
CaMBP Tg, and OV WT CsA mice after 4 wk of treatment typed
for their expression of the various MHCs. n 5 3–4 muscles/group.
The asterisks denote differences (P , 0.05) from CON WT.The Journal of Cell Biology, Volume 151, 2000 670
hand, expression of the CnA* transgene did spare OV-
CsA muscles the manifestation of a shorter, constitutively
active form of CnA, originally detected in failing human
hearts (Tsao et al., 2000). We also show that expression of
a peptide preventing CaM from signaling downstream to
target enzymes (Wang et al., 1995), mimics the effects of
calcineurin inhibitors in blocking OV-induced fiber growth
and fast-to-slow fiber conversions. Taken together, these
results emphasize that calcineurin, in conjunction with
other activation-linked signal transduction events, is im-
portant for the initiation of fiber adaptations to increased
contractile loads, and suggest that unless significantly com-
promised, the endogenous pool of this enzyme can accom-
modate the signaling requirements related to extremes in
functional demand.
Transcription Factors Downstream of Calcineurin
Studies of skeletal myocytes have shown that NFAT and
MEF2 cis-acting control elements are necessary for the
calcineurin-dependent activation of TnIs and myoglobin
promoter-linked reporter constructs (Chin et al., 1998). It
appears that calcineurin may signal to these target genes
via the direct dephosphorylation and transcriptional acti-
vation of NFATc1 and MEF2A (Chin et al., 1998; Mao
and Wiedmann, 1999; Wu et al., 2000). Consistent with
this, we show for the first time that NFATc1, MEF2A, and
MEF2D transcription factors are dephosphorylated, and
MEF2A protein increased, in a calcineurin-dependent
fashion in mature skeletal muscles in vivo in response to
either CnA* expression or OV. Of these, MEF2D appears
to be the preferred target of calcineurin in skeletal muscle
since the dephosphorylation of this protein was more com-
plete than either MEF2A or NFATc1 under these condi-
tions. For the most part, the effect of OV on the dephos-
phorylation of these transcription factors was largely
matched and never potentiated by the effect of the CnA*
transgene. This combined with the finding that both de-
phosphorylation and abundance of MEF2A were mark-
edly greater with OV, suggests that by far, muscle activity-
linked signal transduction elements are major determi-
nants of the signaling flux via calcineurin.
The fact that a gross change in phosphorylation status
was observed for MEF2A and MEF2D, but not MEF2C,
in response to CnA* expression or OV, suggests that only
a subset of MEF2 isoforms (i.e., MEF2A and MEF2D) are
substrates of calcineurin. This notion is supported by the
finding that MEF2A and 2D are more effective than other
MEF2 isoforms in enhancing the calcineurin-dependent
activation of a slow-fiber-specific enhancer (Wu et al.,
2000). Moreover, a MEF2 site implicated in the cal-
cineurin-responsiveness of the Nur77 promoter in T lym-
phocytes is shown to bind only MEF2A and MEF2D pro-
teins (Blaeser et al., 2000). Although the location of the
calcineurin Ser/Thr dephosphorylation site(s) on MEF2A
and MEF2D is not known, findings that the dephosphory-
lation of MEF2 by calcineurin in myocytes and T lympho-
cytes increases its transcriptional activity without affecting
its DNA binding (Woronicz et al., 1995; Wu et al., 2000),
suggest that such a site(s) may lie in a transactivation do-
main conserved in both of these proteins (Black and Ol-
son, 1998). Our MEF2 dephosphorylation findings thus
concur with data showing increased MEF2-dependent
transcription in the fast-twitch EDL under normal weight-
bearing conditions in Tg mice harboring this same MCK-
CnA* construct (Wu et al., 2000).
Matching of Calcineurin Activity to Upstream 
Contractile-dependent Signals
Despite the fact that overexpression of CnA* enhanced the
dephosphorylation of target substrates in the plantaris, it
did not influence slow fiber number or the expression of
slow fiber-specific genes under normal contractile condi-
tions. These results are in sharp contrast to a recent report
of fast to slow fiber transitions in mice that overexpressed
this same transgene at comparable levels (Naya et al.,
2000). These previous data are difficult to reconcile with
ours since fiber transformations were assessed in whole
hindlimb preparations and calcineurin activities not re-
ported. Nonetheless, the fact that a 10-fold overexpression
of CnA* mRNA did not induce fiber hypertrophy in either
study, reinforces the notion that in order to promote skele-
tal muscle fiber growth in vivo, increases in calcineurin ac-
tivity must be matched to upstream activity-dependent ef-
fectors (i.e., contractile loading-related signaling events).
Indeed, the finding that OV MCK-CnA* and OV MLC-
CnA* Tg mice displayed a similar hypertrophic response
and activation of the slow fiber program as WT counter-
parts, suggests that contractile activity is a major determi-
nant of these calcineurin-mediated fiber adaptations. These
data are therefore consistent with our previous notion
(Dunn et al., 1999) that skeletal muscle cell signaling via
calcineurin does not occur to a great extent under normal
contractile conditions, and is only initiated when the nerve-
mediated frequency of Ca21 oscillations becomes higher
than normal as seen under conditions of compensatory
growth (Panchenko et al., 1974). Our findings in skeletal
muscle contrast with those in heart in that expression of
this same CnA* transgene induces cardiac hypertrophy
when driven by the a-MHC promoter in Tg mice (Molken-
tin et al., 1998). The disparate effects of CnA* observed be-
tween cardiac and skeletal muscle may relate to differences
in the strength of the MCK versus a-MHC promoter in
these respective tissues. Alternatively, the possibility exists
that because of the chronically active nature of this cell
type, the threshold requirement of signaling via upstream
activity-linked effectors (i.e., sustained levels of cytosolic
Ca21) is already met under normal cardiac contractile load-
ing conditions.
Regarding the potential identity of these activity-depen-
dent signal transduction events, there is mounting evi-
dence that calcineurin must interact with parallel calcium-
sensitive signaling pathways in order to fully activate
downstream target genes (O’Keefe et al., 1992; Blaeser et
al., 2000; De Windt et al., 2000; Friday et al., 2000; Wu et
al., 2000). For instance, calcineurin synergizes with phor-
bol ester-dependent pathways to stimulate the IL-2 pro-
moter in T lymphocytes and the expression of atrial natri-
uretic factor in cardiomyocytes (O’Keefe et al., 1992; De
Windt et al., 2000). Similarly, calcineurin acts in conjunc-
tion with CaM-dependent kinase IV to fully activate the
myoglobin promoter in cultured skeletal myocytes (Wu et
al., 2000) and the Nur77 promoter in T lymphocytes
(Blaeser et al., 2000). Moreover, retroviral-mediated gene
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in the presence of extracellular Ca21 (Friday et al., 2000).
Additionally, there is evidence that MAP kinase pathways
are activated in response to increased contractile activity
and play a role in regulation of the slow fiber phenotype
(Murgia et al., 2000). In this context, MEF2 is an enticing
candidate as an integrator of calcineurin and other activa-
tion-linked signal transduction pathways, since this tran-
scription factor is both dephosphorylated by calcineurin
and phosphorylated by various CaM kinases, ERK5, p38,
and PKC (Black and Olson, 1998; Wu et al., 2000).
An alternative possibility is that calcineurin signaling
may converge with other activity-linked pathways via the
association of GATA with NFAT (Molkentin et al., 1998;
Musaro et al., 1999). Indeed, activation of calcineurin pro-
motes the association of these two transcription factors via
the dephosphorylation of NFATc1 and increased expres-
sion of GATA-2 under conditions of skeletal myocyte
growth (Musaro et al., 1999). Consistent with findings from
hypertrophic myocytes, we found this protein to be upreg-
ulated in the plantaris in response to OV, but not lowered
by CsA treatment, suggesting that this transcription factor
may be important for growth but not necessarily a gene
target of calcineurin. Given that GATA is also known to
associate with MEF2 (Morin et al., 2000), and that we ob-
served fiber hypertrophy only when NFATc1 and MEF2
were dephosphorylated and GATA-2 increased, leads us
to postulate that NFAT, MEF2, and GATA proteins act in
synergy to transactivate target genes that lead to fiber
growth in response to OV. Future studies should help iden-
tify the particular permutations of these transcription fac-
tors involved in the activation of slow fiber–specific genes
versus those modulating adult fiber size.
Response of Skeletal Muscle to Limited
CnA Availability
Although CnA* expression did not potentiate the fiber
adaptations to OV, it did spare OV-CsA muscles the ap-
pearance of a shorter, COOH terminus deletion variant of
CnA. This variant, resembling a form first identified in
failing human hearts (Tsao et al., 2000), may harbor a de-
letion of the autoinhibitory domain at its COOH terminus
(Fig. 5 a) thereby conferring constitutive activity to this
enzyme (Hubbard and Klee, 1989; O’Keefe et al., 1992). It
is proposed that the manifestation of this shorter form of
CnA may serve as a molecular indicator of injury related
to excessive contractile stress or the inability of the endog-
enous calcineurin pool to meet the signaling requirements
of contractile activity (Tsao et al., 2000). Our finding that
the shorter form of CnA was detected in OV WT plantaris
muscles treated with CsA, but was prevented by CnA* ex-
pression, suggests the latter scenario more likely since
both tissues would have been subjected to the same con-
tractile stress. Though it is not clear at present why the ex-
pression of the transgene blocked this OV- and CsA-sensi-
tive appearance of the CnA variant, it may relate to the
fact that the product of the transgene and this variant are
probably functionally analogous (i.e., constitutively ac-
tive). In this sense, increasing calcineurin activity may be a
valid pharmacological strategy to counter muscle patholo-
gies related to excessive contractile stress (e.g., postpolio
syndrome) or clinical conditions in which signaling via this
enzyme is compromised. Moreover, tissue detection of this
shorter form of CnA may also prove to be a valuable diag-
nostic indicator of a stressed neuromuscular system.
The fact that the shorter form of CnA did not appear in
the plantaris of WT mice in response to OV alone suggests
that the endogenous calcineurin pool is sufficient to ac-
commodate signaling under these conditions. In this re-
spect, skeletal muscle appears to mimic the brain, a tissue
displaying the highest levels of calcineurin, since overex-
pression of CnA* in neurons does not enhance cal-
cineurin-dependent processes such as long-term depres-
sion (Winder et al., 1998). Thus, excitable cells displaying
burst activation profiles such as muscle fibers and neurons
may possess a functional reserve of this enzyme to ensure
that calcineurin-dependent signaling pathways remain
sensitive to the large fluctuations in calcium that may po-
tentially occur in these cell types in response to activation.
CaM Dependency of Skeletal Muscle Adaptation
To further examine the role of calcineurin in the regula-
tion of muscle fiber growth in vivo (Dunn et al., 1999), Tg
mice were generated that overexpressed CaMBP in skele-
tal muscles under the control of the TnIs promoter. This
strategy allowed us to restrict the expression and related
effects of this transgene to slow/type I MHC fibers within
the same muscle. CaMBP is a peptide that would have ac-
tions analogous to calcineurin inhibitors in preventing sig-
naling of CaM to target enzymes. Consistent with our
previous findings using specific calcineurin inhibitors
(Dunn et al., 1999), overexpression of CaMBP com-
pletely blocked hypertrophy of plantaris slow/I MHC fi-
bers which harbored the transgene. Interestingly, expres-
sion of CaMBP also prevented OV-related fast-to-slow
fiber conversions, suggesting that the OV-sensitive initia-
tion of the slow fiber program (i.e., TnIs expression) and
consequent activation of the transgene within plantaris
fast/II MHC fibers resulted in a reverberatory “on-off”
circuit that prevented any further transformation of these
cells. The fact that CaMBP expression did not affect plan-
taris slow fibers under normal weightbearing conditions, is
consistent with the notion that calcineurin is of major im-
portance only when contractile loading is increased above
normal levels (Dunn et al., 1999). Although these results
do not preclude a direct involvement of CaM kinases in
these fiber adaptations, the fact that expression of CaMBP
mimicked the effects of calcineurin inhibitors, emphasizes
the critical role of this phosphatase in regulating fiber
growth and fiber transformations. Finally, since the effects
of the CaMBP transgene are limited to within mature skel-
etal muscle fibers, these findings support our previous con-
clusion (Dunn et al., 1999) that the modulating effect of
calcineurin on fiber growth is likely restricted to events in-
trinsic to the cell rather than to extra-fiber phenomena re-
lated to satellite cell differentiation (Friday et al., 2000).
In summary, we provide evidence that both calcineurin
and its upstream activity-linked effectors are required for
the induction of fiber hypertrophy and fast-to-slow fiber
conversions in response to increased contractile loads. The
fact that calcineurin inhibitors and CaMBP influence fiber
phenotype only under conditions of OV, taken together
with the finding that OV is a major stimulus for calcineurin
signaling via NFATc1 and MEF2 in vivo, reinforces our
previous notion that calcineurin is a major modulator ofThe Journal of Cell Biology, Volume 151, 2000 672
skeletal fiber growth and fiber type transitions only when
cytosolic Ca21 is sustained at levels that are relatively
higher than “normal” as seen under conditions of in-
creased contractile loading (Panchenko et al., 1974). Fu-
ture studies will aim to identify the target genes of calci-
neurin that regulate mature fiber growth and the accessory
signaling events that coordinate with this phosphatase to
initiate OV-induced fiber adaptations.
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